Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients-Reference-Cited by-同舟云学术

Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients

Published:2015-03-23 Issue:5 Volume:61 Page:1523-1532
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Chayama Kazuaki¹,Notsumata Kazuo²,Kurosaki Masayuki³,Sato Ken⁴,Rodrigues Lino⁵,Setze Carolyn⁵,Badri Prajakta⁵,Pilot‐Matias Tami⁵,Vilchez Regis A.⁵,Kumada Hiromitsu⁶

Affiliation:

1. Department of Gastroenterology and MetabolismHiroshima UniversityHiroshima Japan

2. Department of Internal MedicineFukui‐ken Saiseikai HospitalFukui Japan

3. Department of Gastroenterology and HepatologyMusashino Red Cross HospitalMusashino‐shi Tokyo Japan

4. Department of Medicine and Molecular ScienceGunma University Graduate School of MedicineMaebashi Gunma Japan

5. AbbVie, Inc.North Chicago IL

6. Department of HepatologyToranomon HospitalTokyo Japan

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.27705

Reference31 articles.

1. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward)

2. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma

3. Changing Trends in Hepatitis C Infection over the Past 50 Years in Japan

4. Prevalence of Hepatitis C Virus Subgenotypes 1a and 1b in Japanese Patients: Ultra-Deep Sequencing Analysis of HCV NS5B Genotype-Specific Region

5. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Intervention of Serine Protease Inhibitors against Hepatitis C Virus;Current Medicinal Chemistry;2023-10-19

2. Direct‑acting antiviral treatment is safe and effective for chronic HCV patients with psychiatric disorders;Experimental and Therapeutic Medicine;2023-07-07

3. Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study;Therapeutic Innovation & Regulatory Science;2023-05-25

4. A Post-marketing surveillance of ombitasvir/paritaprevir/ritonavir for patients with hepatitis C virus genotype 1b infection: A follow-up study of phase 2 and 3 clinical trials;Kanzo;2022-07-01

5. Surveillance of hepatocellular carcinoma using liver stiffness in patients with hepatitis C after sustained virologic response by direct-acting antivirals;Kanzo;2022-06-01